The European Commission will let Gilead sell remdesivir to its 27-country bloc while scientists continue to study the antiviral as a COVID-19 treatment, making it the first drug conditionally approved to treat the virus in the European Union. “This is an important step forward in our efforts against COVID-19. We will leave no stone unturned to provide our citizens with access to safe and effective therapies,” Stella Kyriakides, EU commissioner for health and food safety, tweeted upon hearing the news...